Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Extramedullary disease (EMD) predicts poor outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM). KQ-2003 is a bicistronic BCMA/CD19 CAR T-cell product incorporating 4-1BB and CD28-YMFM costimulatory domains. We assessed its activity and intralesional biology, focusing on EMD. METHODS: sensitivity). Progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox methods. Longitudinal single-cell RNA sequencing profiled one patient's infusion product, serial blood, and spatially distinct EMD biopsies. RESULTS: Patients had received a median of five prior lines; 18 (75.0%) were triple-class refractory, six (25.0%) penta-refractory, 23 (95.8%) had high-risk cytogenetics, and 15 (62.5%) had EMD. All 20 patients with measurable hematologic disease achieved hematologic responses (18 [90.0%] complete/stringent complete); IMWG-defined overall response rate was 95.0%. Fourteen (93.3%) of 15 EMD patients achieved metabolic responses (13 [86.7%] complete). Among 19 baseline MRD-positive patients, 12 (63.2%) became MRD-negative by month 6; 10 and six also had documented negativity at months 12 and 24, respectively. At 29.2 months' median follow-up, median PFS was 24.0 months (95% CI, 15.0-not reached); no significant difference was detected by baseline EMD status (HR, 0.92; P = 0.89). Among the 21 trial participants, grade ≥ 3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in one (4.8%) and two (9.5%), respectively; two treatment-related fatal pneumonias occurred. Single-patient longitudinal profiling revealed proliferating lesion-infiltrating CAR T cells with increased CCL3/CCL4 expression and tumor-cell apoptotic and necroptotic transcriptional programs. Trajectory analysis suggested transcriptional links between tissue effectors and circulating CCL5-positive memory-like CAR T cells. CellChat predicted BCMA-related tumor-microenvironment interactions and immune-cell interactions involving circulating CAR T cells. CONCLUSIONS: KQ-2003 produced deep, durable hematologic and metabolic responses in heavily pretreated, high-risk RRMM, including EMD. Intralesional profiling identified CAR T-cell proliferation, tumor-cell death-associated programs, and candidate microenvironmental interactions. These findings warrant further evaluation of this dual-targeting strategy in EMD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04714827; registered 19 January 2021.
Source: Journal of Hematology & Oncology
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W7236032155
